US 11,684,605 B2
Lisinopril compositions with an ingestible event marker
Kurt Scheinpflug, Dublin, CA (US); Nikhil Pargaonkar, Hayward, CA (US); Chris Dong, Redwood City, CA (US); Ai Ling Ching, San Francisco, CA (US); and Dawn Adkin, Loughborough (GB)
Assigned to OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed by OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed on Oct. 6, 2021, as Appl. No. 17/495,773.
Application 17/495,773 is a continuation of application No. 15/962,614, filed on Apr. 25, 2018, granted, now 11,166,939.
Claims priority of provisional application 62/490,010, filed on Apr. 25, 2017.
Prior Publication US 2022/0079919 A1, Mar. 17, 2022
Int. Cl. G08B 21/04 (2006.01); A61K 31/401 (2006.01); A61B 5/07 (2006.01); A61B 5/06 (2006.01); A61B 5/00 (2006.01); A61P 9/12 (2006.01); A61P 13/12 (2006.01); A61P 9/10 (2006.01); A61P 9/04 (2006.01); A61K 9/20 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 49/00 (2006.01)
CPC A61K 31/401 (2013.01) [A61B 5/068 (2013.01); A61B 5/073 (2013.01); A61B 5/4833 (2013.01); A61B 5/4839 (2013.01); A61K 9/1652 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/485 (2013.01); A61K 9/4816 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 49/00 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 13/12 (2018.01); A61B 2560/0204 (2013.01); A61B 2560/0214 (2013.01); A61B 2562/08 (2013.01); A61B 2562/12 (2013.01)] 11 Claims
OG exemplary drawing
 
1. An ingestible composition comprising:
1) about 10% w/w lisinopril;
about 15% w/w dicalcium phosphate, dihydrate;
about 53.85% w/w mannitol (50 um);
about 10% w/w pregelatinized starch; OR
2) about 7.3% w/w lisinopril;
about 30% w/w dicalcium phosphate, dihydrate;
about 24.6% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR
3) about 10.21% w/w lisinopril;
about 15.31% w/w dicalcium phosphate, dihydrate;
about 58.02% w/w mannitol (180 um);
about 15.31% w/w pregelatinized starch; OR
4) about 9.69% w/w lisinopril;
about 14.53% w/w dicalcium phosphate, dihydrate;
about 55.09% w/w mannitol (180 um);
about 14.53% w/w pregelatinized starch; OR
5) about 9.18% w/w lisinopril;
about 13.76% w/w dicalcium phosphate, dihydrate;
about 52.16% w/w mannitol (180 um);
about 13.76% w/w pregelatinized starch; OR
6) about 18.18% w/w lisinopril;
about 1318% w/w dicalcium phosphate, dihydrate;
about 47.59% w/w mannitol (50 um);
about 10% w/w pregelatinized starch; OR
7) about 18.18% w/w lisinopril;
about 14.32% w/w dicalcium phosphate, dihydrate;
about 51.36% w/w mannitol (50 um);
about 5% w/w pregelatinized starch; OR
8) about 7.27% w/w lisinopril;
about 30% w/w dicalcium phosphate, dihydrate;
about 24.58% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR
9) about 10% w/w lisinopril;
about 28% w/w dicalcium phosphate, dihydrate;
about 22.85% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR
10) about 10.26% w/w lisinopril;
about 15.38% w/w dicalcium phosphate, dihydrate;
about 58.32% w/w mannitol (180 um);
about 15.38% w/w pregelatinized starch; OR
11) about 10.16% w/w lisinopril;
about 15.23% w/w dicalcium phosphate, dihydrate;
about 57.73% w/w mannitol (180 um);
about 15.23% w/w pregelatinized starch; OR
12) about 10.05% w/w lisinopril;
about 15.07% w/w dicalcium phosphate, dihydrate;
about 57.14% w/w mannitol (180 um);
about 15.07% w/w pregelatinized starch; OR
13) about 10.1% w/w lisinopril;
about 15.15% w/w dicalcium phosphate, dihydrate;
about 57.44% w/w mannitol (180 um);
about 15.15% w/w pregelatinized starch; OR
14) about 10% w/w lisinopril;
about 15% w/w dicalcium phosphate, dihydrate;
about 56.85% w/w mannitol (180 um);
about 15% w/w pregelatinized starch; OR
15) about 9.74% w/w lisinopril;
about 14.61% w/w dicalcium phosphate, dihydrate;
about 55.39% w/w mannitol (180 um);
about 14.61% w/w pregelatinized starch; OR
16) about 10.62% w/w lisinopril;
about 15.92% w/w dicalcium phosphate, dihydrate;
about 57.18% w/w mannitol (180 um);
about 10.62% w/w pregelatinized starch; OR
17) about 10.06% w/w lisinopril;
about 15.08% w/w dicalcium phosphate, dihydrate;
about 54.16% w/w mannitol (180 um);
about 10.06% w/w pregelatinized starch; and
an ingestible identifier comprising:
an integrated circuit comprising silicon, aluminum, silicon dioxide, and silicon nitride;
a wafer comprising titanium, titanium-tungsten, gold, magnesium, copper (I) chloride, and hydroxypropyl cellulose; and
a skirt film comprising ethyl cellulose, hydroxypropyl cellulose, and triethyl citrate.